23 Jul Nintedanib 100 mg Cipla and Nintedanib 150 mg Cipla
| Company name & Address: | registration number | Batch number(s) | Expiry date | Pack size | First release date | Re-call Classification | Recall date |
| Cipla Medpro (Pty) Ltd. Building 2 Junxion Park 10 Elephant Lane Century City South Africa 7441 |
56/26/0704.702 56/26/0705.703 |
6KA0781 6KA0782 |
01.2028 |
60’s |
14.04.2026 14.04.2026 |
Class II Type B |
21 July 2026 |
Brief description of the problem (reason for recall)
This recall is initiated as a result of product quality complaints received due to soft-gel capsules clumping/sticking together.
Advice for health professionals and distributors:
Cipla requests that you refrain from selling or dispensing any pack of the affected batches of Nintedanib 100 mg and 150 mg Cipla and return the products to your supplying warehouse or distributor with immediate effect for a full credit/replacement.
For further product information, please call Cipla Medpro (Pty) Ltd. Customer Care line (080 222 6662).
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points and the recall process was initiated.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.